Back to search
FDAFDA · Food and drugs·Recall number D-0791-2022

Zonisamide Capsules USP, 25 mg, packaged in 100-count bottles, Rx Only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-128-01

Published May 4, 2022 · Recall initiated: April 25, 2022

Summary

FDA records drug Class II recall D-0791-2022, published May 4, 2022 and initiated April 25, 2022. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Completed; Reported quantity: 11,136 bottles; Lot: Lot #: 29200052, Exp 4/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if ZONISAMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ZONISAMIDE
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Distributor
USA nationwide
UPC
0368462130018
Lot
Lot #: 29200052, Exp 4/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Zonisamide Capsules USP, 25 mg, packaged in 100-count bottles, Rx Only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-128-01 recalled?

Yes. FDA published recall D-0791-2022 on May 4, 2022. Reported hazard: cGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ZONISAMIDE. UPC: 0368462130018.